Quality of life from the perspective of the patient with acute myeloid leukemia.

ABSTRACT:

Background

Although outcomes for acute myeloid leukemia (AML) have improved over time, they remain poor overall, and toxicity from both the disease and its treatment can affect quality of life (QOL). One barrier to including QOL endpoints in clinical trials is the lack of a disease-specific QOL instrument that can efficiently capture the major QOL deficits in this population.

Methods

A cross-sectional study was performed to elicit concepts for inclusion in a new AML-specific QOL instrument called the AML-QOL. Eighty-two patients at various stages of disease were interviewed about sources of support (positive concepts) and problems and symptoms (negative concepts) experienced over the past week, and they were asked to grade how much each affected their QOL. In addition, patie

SUBMITTER: Buckley SA 

PROVIDER: S-EPMC5749925 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature